Abstract:Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive decline in multiple cognitive domains and it becomes the most common cause of dementia in the elderly. There is an urgent need for the early diagnosis and treatment of AD to ease caregiver burden and medical costs, as well as improve patients' living activities associated with the dramatic increasing number of affected individuals. Molecular imaging with target-specific probes is contributing to identify the underlying biology in AD, which benefits to the early diagnosis of AD and the evaluation of anti-AD therapy. Molecular imaging probes, such as C-11-PIB, C-11-MP4A, F-18-AV-45, and F-18-FDG, can selectively bind to special bimolecular of AD or accurately accumulate at the location of damage areas, thus become an edge tool for a better management of the diseases in the clinical practice and new drug development. In the past decades, a large variety of probes is being developed and tested to be useful for the early and accurate diagnosis of Alzheimer's disease, patient selection for disease-modifying therapeutic trials and monitoring the effect of anti-amyloid therapy. Since imaging probes may also help to guide physicians to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug, this paper is to present a perspective of the available imaging probes for AD, classified on different modalities. Meanwhile, recent advances of those probes that have been selected for clinical trials and are at the different stages of the US Food and Drugs Administration (FDA) approval are outlined. Additionally, future directions and specific application of imaging strategies designed for both diagnosis and treatment for AD are discussed.

Recent Advances in Fabricating the Multifunctional A beta Small Organic Molecule Probes for Theranostic Application

Recent Research Progress in Fluorescent Probes for Detection of Amyloid- In Vivo

N-methylbenzothiazolium based theranostics as fluorescence imaging and photo-oxidation agents for Amyloid-β

Research Progress Of Multi-Functional Fluorescent Probes For Alzheimer'S Disease Monitoring

Light-controlled Fluorescent Probes for Precisely Monitoring Brain Amyloid-Β Aggregates in Alzheimer's Disease

A Novel Viscosity Sensitive Hemicyanine Fluorescent Dye for Real-Time Imaging of Amyloid-Β Aggregation

Current strategies for the development of fluorescence-based molecular probes for visualizing the enzymes and proteins associated with Alzheimer’s disease

Advances in development of fluorescent probes for detecting amyloid-β aggregates

Shedding Light on Alzheimer's Disease: Recent Advances in Highly Selective Fluorescent Probes

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

Recent Progress of Small-Molecule-based Theranostic Agents in Alzheimer's Disease

Multifunctional Theranostic Carbazole-Based Cyanine for Real-Time Imaging of Amyloid-β and Therapeutic Treatment of Multiple Pathologies in Alzheimer's Disease

Rational design synthesis and evaluation of a novel near-infrared fluorescent probe for selective imaging of amyloid-β aggregates in Alzheimer's disease

An AIE-active Theranostic Probe for Light-Up Detection of Aβ Aggregates and Protection of Neuronal Cells.

Synthesis and evaluation of curcumin-based near-infrared fluorescent probes for detection of amyloid β peptide in Alzheimer mouse models

Curcumin Complex Analogues as Near-Infrared Fluorescent Probes for Monitoring all A beta Species in the Early Alzheimer's Disease Model

Application of Biomarker-Derived Fluorescent Probes for the Detection of Alzheimer's Disease

Past And Recent Progress Of Molecular Imaging Probes For Beta-Amyloid Plaques In The Brain

Design of Multifunctional Agent Based on Basified Serum Albumin for Efficient in Vivo Β-Amyloid Inhibition and Imaging.

Current strategies of detecting Aβ species and inhibiting Aβ aggregation: Status and prospects

A Beta-Binding Molecules: Possible Application As Imaging Probes And As Anti-Aggregation Agents